MACHINE LEARNING FOR HAEMOPHILIA SEVERITY ASSESSMENT AND PROPHYLAXIS PRIORITY WITH CHAT ASSISSTANCE

Dr. Naresh Patel K M[1] ,Akshaya J H[2] , Ananya Patted[3] , Pruthvi K P[4] , Raghavendra M[5],

Associate Professor, Department of Computer Science and Engineering, Bapuji Institute of Engineering and Technology, Davangere, Karnataka, India[1]

B.E Student, Department of Computer Science and Engineering, Bapuji Institute of Engineering and Technology, Davangere, Karnataka, India[2]

B.E Student, Department of Computer Science and Engineering, Bapuji Institute of Engineering and Technology, Davangere, Karnataka, India[3]

B.E Student, Department of Computer Science and Engineering, Bapuji Institute of Engineering and Technology, Davangere, Karnataka, India[4]

B.E Student, Department of Computer Science and Engineering, Bapuji Institute of Engineering and Technology, Davangere, Karnataka, India[5]

ABSTRACT: Haemophilia, a rare bleeding disorder, poses significant challenges in managing patient care, particularly in determining the severity of the condition and prioritizing prophylactic interventions. This research explores the integration of machine learning (ML) algorithms to enhance the assessment of haemophilia severity and facilitate personalized prophylaxis recommendations. The primary objective is to develop a comprehensive model capable of accurately predicting haemophilia severity levels for individual patients. By utilizing large datasets encompassing diverse patient profiles, the ML model learns complex patterns and associations, allowing it to provide precise severity assessments. The integration of natural language processing (NLP) techniques facilitates the extraction of valuable information from textual medical records and patient interviews, contributing to a more holistic understanding of the disease progression. In addition to severity assessment, the research introduces a novel approach to prioritize prophylaxis strategies using the ML model. The chat assistance feature adds an interactive dimension to the system, fostering communication between patients and healthcare providers, ultimately leading to more informed and collaborative decision-making in the management of haemophilia.

KEYWORDS: Haemophilia, Severity assessment, Machine Learning, Random-forest Algorithm

I. INTRODUCTION

Haemophilia, a rare but significant genetic bleeding disorder, has captivated the attention of the medical community for centuries due to its unique challenges and the impact it has on individuals. This disorder, often recognized for its historical association with European royalty, arises from deficiencies in specific clotting factors, leading to prolonged bleeding and impaired blood clot formation. This introduction aims to unravel the intricate facets of haemophilia, shedding light on its factors, causes, types, assays, and the profound consequences it imposes on those affected.

Genetic Factors: At the heart of haemophilia lies a genetic predisposition that is inherited through the X chromosome. Unlike most genetic disorders, haemophilia primarily affects males, as they possess only one X chromosome. Females, with two X chromosomes, act as carriers and may transmit the disorder to their offspring. The key genetic factors involved are alterations in the genes responsible for encoding clotting factor VIII (Haemophilia A) or factor IX (Haemophilia B). These factors are integral components of the intricate cascade that leads to blood clot formation

Causes of Haemophilia: The causative factor for haemophilia is a mutation in the specific genes associated with clotting factors. These mutations result in the inadequate production or dysfunction of clotting factors VIII or IX. The majority of cases are inherited, with affected individuals receiving the mutated gene from their carrier mothers. In rare instances,

spontaneous mutations can lead to haemophilia, even in the absence of a family history. Understanding the genetic underpinnings of haemophilia is crucial for accurate diagnosis, prognosis, and the development of targeted treatment strategies.

Types of Haemophilia: Haemophilia manifests in two main types: Haemophilia A and Haemophilia B. Haemophilia A, the more prevalent type, arises from a deficiency in clotting factor VIII, while Haemophilia B results from a deficiency in factor IX. The severity of haemophilia is categorized into mild, moderate, and severe, depending on the residual activity of the affected clotting factor. These distinctions guide healthcare providers in tailoring treatment plans and assessing the potential risks associated with bleeding episodes.

Assays for Diagnosis: Diagnosing haemophilia involves specialized laboratory assays to measure the levels and activity of clotting factors in the blood. The Partial Thromboplastin Time (PTT) is a common test used to assess the intrinsic pathway of coagulation, often prolonged in haemophilia. Specific factor assays, including Factor VIII and IX assays, provide quantitative information about the concentration and functionality of the deficient clotting factors. Molecular genetic testing is also employed to identify the specific mutations responsible for haemophilia, aiding in genetic counseling and family planning.

Consequences of Haemophilia: The consequences of haemophilia extend beyond the immediate challenges of bleeding episodes. Individuals with haemophilia, especially those with severe forms, face the risk of spontaneous bleeding into joints and muscles, leading to chronic pain, joint deformities, and mobility issues. Additionally, the recurrent need for clotting factor replacement therapy poses a financial and logistical burden on patients and healthcare systems. The psychological impact of living with a chronic bleeding disorder, coupled with the potential complications of treatment, necessitates a holistic approach to care, encompassing physical, emotional, and social well-being. In conclusion, haemophilia stands as a testament to the intricate interplay between genetics, coagulation pathways, and the challenges posed by a bleeding disorder. As we delve into the details of haemophilia, from its genetic origins to the diagnostic assays employed for its detection, a comprehensive understanding emerges. The quest for effective management and treatment of haemophilia requires a multidisciplinary approach that integrates genetic insights, advanced laboratory techniques, and a compassionate understanding of the profound consequences faced by those affected by this complex disorder.

Haemophilia Severity Assessment: Accurate assessment of haemophilia severity is crucial for tailoring treatment plans to individual patients. Machine learning offers a dynamic approach by analyzing a myriad of patient-specific data, including genetic factors, bleeding history, and treatment responses. The ML model learns complex patterns and correlations, providing a nuanced understanding of the disease's progression for each patient. This level of precision enables healthcare providers to anticipate and address potential complications, optimizing the overall quality of care.Traditional methods of assessing haemophilia severity have relied on empirical clinical judgments and limited datasets. Machine learning, however, allows for the incorporation of diverse and extensive datasets, enabling the identification of subtle patterns that might escape human observation. By analyzing genetic factors, which play a crucial role in determining the severity of haemophilia, along with historical bleeding episodes and treatment responses, machine learning models can develop a comprehensive and individualized severity profile for each patient. Moreover, the dynamic nature of machine learning allows for continuous learning and adaptation to changes in a patient's condition over time. This adaptability ensures that the severity assessment remains accurate and relevant throughout the course of treatment. By moving beyond static severity classifications, machine learning contributes to a more personalized and responsive approach to haemophilia care.

Dosage Calculation: Determining the appropriate dosage for haemophilia treatment is often a delicate balance, and machine learning brings a data-driven approach to refine this process. By analyzing factors such as clotting factor levels, treatment adherence, and individual response patterns, the machine learning algorithm calculates optimal dosage regimens tailored to each patient's needs. This ensures not only the efficacy of treatment but also minimizes the risk of complications such as overmedication or inadequate response. The traditional approach to dosage calculation has been based on standardized regimens and clinical judgment. However, this one-size-fits-all approach does not account for the considerable variability in patient responses to treatment. Machine learning models, on the other hand, can analyze a diverse range of factors that influence dosage requirements, including genetic variations that affect clotting factor metabolism and clearance rates. The use of machine learning in dosage calculation also facilitates real-time adjustments based on a patient's evolving condition. This adaptability is particularly crucial in a disorder like haemophilia, where factors such as age, physical activity, and other health conditions can impact the patient's response to treatment. By continuously learning from new data, the machine learning model can refine dosage recommendations, ensuring that patients receive the most effective and personalized treatment.

Prophylaxis Priority: Prophylactic interventions aim to prevent bleeding episodes and joint damage in individuals with haemophilia. Bleeding frequency, joint health, and treatment adherence are analyzed to create a personalized prophylaxis plan. This proactive approach not only improves patient outcomes but also contributes to a more efficient allocation of healthcare resources. Historically, prophylactic treatment decisions have been based on a combination of clinical experience and generalized guidelines. Machine learning introduces a paradigm shift by considering a multitude of patient-specific factors in prophylaxis prioritization. The model analyzes historical bleeding frequency, the overall health of joints, and the patient's adherence to treatment plans to formulate a personalized prophylaxis strategy. By identifying high-risk periods and tailoring prophylactic interventions accordingly, machine learning contributes to a more effective and resource-efficient haemophilia management strategy. This approach not only minimizes the occurrence of debilitating bleeding episodes but also reduces the burden on healthcare resources by focusing prophylactic measures on individuals who stand to benefit the most.

Chat Assistance Interface: In the landscape of haemophilia care, where precision and timely interventions are paramount, the integration of machine learning techniques has shown great promise. One facet of this transformative approach involves the utilization of chat assistance, which goes beyond conventional FAQ systems, offering a dynamic and interactive interface between patients, healthcare providers, and the machine learning system. Traditional methods of patient communication often rely on static Frequently Asked Questions documents, which may provide information but lack the adaptive and responsive nature required for effective healthcare management. The introduction of a chat assistance interface aims to bridge this gap, creating a real-time, user-friendly platform for communication that enhances patient for communication.

Blood Donor Management: Blood donor management involves the systematic organization and coordination of blood donation campaigns and initiatives to ensure an adequate and safe blood supply for medical treatments and emergencies. A crucial aspect of donor management is the notification and scheduling of blood Haemophilia severity assessment donation appointments to maintain a consistent supply of blood products. To achieve this, donors are informed of their donation schedule based on established guidelines. For male donors, it is typically recommended to donate blood every three months, while female donors are advised to donate every four months due to physiological differences and the need to replenish iron stores. Additionally, the management system keeps records of past donations for each donor, ensuring that their history of contributions is accurately documented. This allows for the efficient tracking of donation frequency and helps identify regular donors who have consistently contributed to the blood supply over time. By implementing effective donor notification systems and maintaining comprehensive donor records, blood donor management programs can optimize blood donation scheduling, promote regular participation, and ensure a reliable blood supply for patients in need.

MACHINE LEARNING (ML) Machine Learning (ML) is a subfield of artificial intelligence (AI) that focuses on developing algorithms and models that enable computers to learn and make predictions or decisions without being explicitly programmed. The fundamental idea behind machine learning is to allow computers to learn from data and improve their performance over time, adapting to new information and experiences. Here's a brief introduction to key concepts in machine learning:

1. Learning from Data: In traditional programming, humans write explicit instructions for computers to perform tasks. In machine learning, computers learn from data. The learning process involves identifying patterns, relationships, and trends within datasets, allowing the system to generalize and make predictions on new, unseen data.

2. Types of Learning:
- **Supervised Learning:** The algorithm is trained on a labeled dataset, where the input data is paired with corresponding output labels. The model learns to map inputs to outputs, making predictions on new, unseen data.
- **Unsupervised Learning:** The algorithm is given unlabeled data and must find patterns or structures within the data without explicit guidance. Common tasks include clustering and dimensionality reduction [21].

3. Key Components:
- **Features and Labels:** In supervised learning, features are the input variables, and labels are the corresponding outputs. The model learns to associate features with labels during training
- **Training and Inference:** During the training phase, the model learns from the data. In the inference phase, the trained model makes predictions on new, unseen data.
- **Model Evaluation:** Assessing the performance of a machine learning model is crucial. Metrics such as accuracy, precision, recall, and F1 score are commonly used to evaluate a model's effectiveness.

4. Common Algorithms:

- **Linear Regression:** Predicts a continuous output based on input features.
- **Decision Trees:** Hierarchical structures that make decisions based on input features.

RANDOM FOREST ALGORITHM: Random Forest is a versatile and powerful algorithm in the realm of supervised learning, renowned for its robustness and effectiveness across various domains. It belongs to the ensemble learning family, where multiple models are combined to enhance predictive performance. Unlike traditional decision trees, which can be prone to overfitting and variance, Random Forest mitigates these issues by constructing a multitude of decision trees and aggregating their predictions. At its core, Random Forest operates by creating a forest of decision trees during training. Each tree is built using a random subset of the training data and a random subset of the features. This randomness injects diversity into the individual trees, making them less correlated and thus less susceptible to overfitting. During inference, predictions from all the trees are combined through averaging (for regression tasks) or voting (for classification tasks), resulting in a robust and stable final prediction. This ensemble approach improves generalization performance and enhances the model's ability to handle unseen data. One of the key advantages of Random Forest is its capability to handle large datasets with high dimensionality and mixed data types without requiring extensive preprocessing. Additionally, it can automatically handle missing values and maintain accuracy even with a large number of irrelevant features. Moreover, Random Forest provides useful insights into feature importance, allowing practitioners to identify the most influential features in the dataset. This feature selection capability aids in understanding the underlying patterns and relationships within the data, facilitating better decisionmaking in various applications. Despite its effectiveness, Random Forest does have some limitations. It may not perform well on highly imbalanced datasets, where one class significantly outnumbers the others. Additionally, the interpretability of the model can be limited compared to simpler algorithms like decision trees. In ensemble learning, different models, often of the same type or different types, team up to enhance predictive performance. It's all about leveraging the collective wisdom of the group to overcome individual limitations and make more informed decisions in various machine learning tasks. Some popular ensemble models include- XGBoost, AdaBoost, LightGBM, Random Forest, Bagging, Voting etc.

- **Bagging:** Bagging is an ensemble learning model, where multiple week models are trained on different subsets of the training data. Each subset is sampled with replacement and prediction is made by averaging the prediction of the week models for regression problem and considering majority vote for classification problem.
- **Boosting**: Boosting trains multiple based models sequentially. In this method, each model tries to correct the errors made by the previous models. Each model is trained on a modified version of the dataset, the instances that were misclassified by the previous models are given more weight. The final prediction is made by weighted voting. The random Forest algorithm works in several steps which are discussed below:
- **Ensemble of Decision Trees:** Random Forest leverages the power of ensemble learning by constructing an army of Decision Trees. These trees are like individual experts, each specializing in a particular aspect of the data. Importantly, they operate independently, minimizing the risk of the model being overly influenced by the nuances of a single tree.
- Random Feature Selection: To ensure that each decision tree in the ensemble brings a unique perspective, Random Forest employs random feature selection. During the training of each tree, a random subset of features is chosen. This randomness ensures that each tree focuses on different aspects of the data, fostering a diverse set of predictors within the ensemble.
- **Bootstrap Aggregating or Bagging**: The technique of bagging is a cornerstone of Random Forest's training strategy which involves creating multiple bootstrap samples from the original dataset, allowing instances to be sampled with replacement. This results in different subsets of data for each decision tree, introducing variability in the training process and making the model more robust.
- **Decision Making and Voting:** When it comes to making predictions, each decision tree in the Random Forest casts its vote. For classification tasks, the final prediction is determined by the mode (most frequent prediction) across all the trees. In regression tasks, the average of the individual tree predictions is taken. This internal voting mechanism ensures a balanced and collective decision-making process.

II. LITREATURE SURVEY

LITERATURE SURVEY REVIEW

In order to get required knowledge about various concepts related to the present application, existing literature was studied. Some of the important conclusions were made through those are listed below.

 [1]Anurag Singh, Shalini Rawat, Rashmi Kushwaha. Clinicopathological Parameters of Haemophilia Patients at Tertiary Care Centre in Northern India It investigates the clinical parameters of haemophiliac patients, emphasizing the

need for understanding the condition in resource-limited areas of developing countries. Among 385 cases, 86.75% were haemophilia A, 13.25% were haemophilia B, with varying severity. Joint bleeding was the most common clinical manifestation. Additionally, a small percentage of patientsshowed positive screening for blood borne infections. The study underscores the importance of considering haemophilia in patients presenting with specific bleeding symptoms and emphasizes the need for prompt diagnostic evaluation.

[2]Agios Loukas. An Overview of Chatbot Technology It provides an overview of the evolution and applications of chatbots in diverse fields, including marketing, education, healthcare, and entertainment. It discusses motivations for using chatbots, their relevance in different areas, and the influence of social stereotypes on their design. The paper also covers technological concepts, chatbot classification, architecture, and platforms for development, highlighting the promising future of chatbot research.

[3]Rohan Pratap, Monali Misra, Varun N, Jayachandra Reddy. The existing scenario of haemophilia care in Canada and China Haemophilia, an X-linked recessive genetic disorder, affects about 400,000 individuals globally. Disparities in healthcare systems, budget constraints, and cultural factors pose challenges for delivering ideal care. physiotherapy and rehabilitation. This review compares hemophilia care in economically unequal countries, highlighting variations in epidemiology, care standards, and challenges in Canada and China, emphasizing the importance of resource allocation and patient access.

 [4]Thromb J. Aspects of prophylactic treatment of haemophilia Both retrospective and prospective studies strongly recommend initiating prophylactic treatment for severe haemophilia A or B in early childhood, ideally before the first joint bleed. The treatment plan should be customized based on treatment goals, venous access, and the patient's bleeding pattern. Early experiences with factor concentrates can impact the risk of developing inhibitors. Long-acting products, particularly in haemophilia B, aid in managing patients with challenging venous access and achieving higher trough levels. Additionally, evidence supports the benefits of prophylactic treatment in adults and patients with inhibitors.

 [5]Johny Mahlangu, Jerry S. Powell, Margaret V. Phase 3 study of recombinant factor VIII Fc fusion protein in severe haemophilia It assessesthe safety, efficacy, and pharmacokinetics of rFVIIIFc in 165 previously treated males with severe haemophilia A. It compared individualized prophylaxis, weekly prophylaxis, and episodic treatment. rFVIIIFc demonstrated an extended half-life, low bleeding rates, and no inhibitor development, making it a well-tolerated option for prophylactic treatment in severe haemophilia A patient.

[6]Uma Jadhav, Kanchan Mukherjee, Harshad Thakur. Usage of Complementary and Alternative Medicine among Severe Haemophilia A Patients in India India reveals a relatively high usage (42.3%) of complementary and alternative medicine among severe haemophilia A patient. Factors linked to usage include economic status, comorbidity, and the education of household heads. These alternative therapies incurred higher costs (17.22%) compared to conventional hemostatic drugs.

 [7] Tiago J. S. Lopes, Ricardo Rios, Tatiane Nogueira, and Rodrigo F. Mello. Prediction of haemophilia A severity using a small-input machine-learning framework It introduces Hema-Class, a machine learning framework predicting haemophilia A severity based on Factor VIII protein structure. Addressing the rarity and severity of Haemophilia A, it explores alternative representations of protein structure and uses ML to analyse properties comprehensively. Validated through assays and clinical reports, Hema-Class accurately predicts mutation impacts, highlighting detrimental hotspots. This approach enhances understanding of Factor VIII, contributing to improved haemophilia A treatment. The study showcases machine learning's potential in predicting rare genetic disorder outcomes, paving the way for advancements in personalized therapies for Haemophilia A and other rare diseases.

[8] Adele Cutler, D. Richard Cutler, John R. Stevens. Random Forests It discusses the Random Forest algorithm for classification and regression emphasizing the use of out-of-bag data, practical issues, and variable importance. It includes examples of regression trees using cancer data and illustrates the impact of different weights on variable importance. The potential usefulness of visualization using the proximity matrix with microarray data is also highlighted. The document provides references to extensions of the Random Forest method and related machine learning techniques.

[9] A. Srivastava, A.K. Brewer, E.P Mauser-Bunschoten, N.S. Key. Guidelines for the management of haemophilia Haemophilia is a rare disorder that is complex to diagnose and to manage. These evidence-based guidelines offer practical recommendations on the diagnosis and general management of haemophilia, as well as the management of complications including musculoskeletal issues, inhibitors, and transfusion-transmitted infections. By compiling these guidelines, the World Federation of Haemophilia aims to assist healthcare providers seeking to initiate and/or maintain haemophilia care programs, encourage practice harmonization around the world and, where recommendations lack adequate evidence, stimulate appropriate studies.

[10] Tiago J. S. Lopes, Ricardo Rios, Tatiane Nogueira, and Rodrigo F. Mello. Prediction of hemophilia A severity using a small-input machine-learning framework It introduces Hema-Class, a machine learning framework predicting hemophilia A severity based on Factor VIII protein structure. Addressing the rarity and severity of hemophilia A, it explores alternative representations of protein structure and uses ML to analyze properties comprehensively Validated through assays and clinical reports, Hema-Class accurately predicts mutation impacts, highlighting detrimental hotspots.

This approach enhances understanding of Factor VIII, contributing to improved hemophilia A treatment. The study showcases machine learning's potential in predicting rare genetic disorder outcomes, paving the way for advancements in personalized therapies for hemophilia A and other rare diseases.

[11] Adele Cutler, D. Richard Cutler, John R. Stevens. Random Forests It discusses the Random Forest algorithm for classification and regression emphasizing the use of out-of-bag data, practical issues, and variable importance. It includes examples of regression trees using cancer data and illustrates the impact of different weights on variable importance. The potential usefulness of visualization using the proximity matrix with microarray data is also highlighted. The document provides references to extensions of the Random Forest method and related machine learning techniques

III.PROPOSED SYSTEM

The proposed system comprises a sophisticated machine learning severity assessment module, which accurately evaluates the severity of haemophilia for each patient, enabling precise treatment decisions. Prophylaxis strategies are then optimized based on patient-specific factors, leveraging the insights gleaned from the severity assessment. An intuitive chat assistance interface provides realtime support, facilitating seamless communication between patients and healthcare providers, while also offering educational resources and adherence reminders. Additionally, a dynamic dosage adjustment module ensures that treatment plans are continuously fine-tuned to meet evolving patient needs. Through comprehensive user training and education initiatives, the implemented system has revolutionized haemophilia care, delivering accurate assessments, personalized treatments, and timely support, thereby significantly enhancing the quality of life for haemophilia patients and optimizing the efforts of healthcare providers.

IV.METHODOLOGY

The methodology for machine learning in haemophilia management is a systematic approach designed to create an integrated and adaptive system. Beginning with data collection from diverse sources, including reputable repositories and medical databases, the project ensures a comprehensive dataset. Subsequent data preprocessing involves normalization to extract meaningful information and ensure uniformity. The severity assessment model employs supervised machine learning, utilizing features like genetic factors and bleeding history. Similarly, a dosage calculation model is developed, considering clotting factor levels and treatment adherence. Supervised learning algorithms are employed to prioritize prophylaxis strategies based on bleeding frequency and joint health. To enhance user interaction, a user-friendly chat interface is implemented using Natural Language Processing techniques, integrated with severity assessment, dosage calculation, and prophylaxis priority models. Model evaluation is rigorous, utilizing metrics such as accuracy and precision, with validation on separate test datasets for generalizability. User training is provided for healthcare providers to interpret model outputs effectively, along with educational materials for patient awareness. In essence, this methodology aims to create a holistic, personalized haemophilia management system, emphasizing ethical practices, security, and continuous improvement. The integration of machine learning models and a user-friendly interface seeks to revolutionize care, offering tailored solutions for improved patient outcomes in the dynamic field of haemophilia management.

**Fig 4.1 Methodology diagram**

V. RESULTS

**Fig.5.1.1 login page**

Fig.5.1.2 Dashboard

Fig.5.1.3 Severity and Dosage Calculations

VI .CONCLUSION

The integration of machine learning for haemophilia severity assessment and prophylaxis priority, with user-friendly chat assistance, holds significant promise for advancing personalized healthcare in haemophilia management. The severity assessment model demonstrates the capability to categorize haemophilia cases accurately, providing healthcare professionals and patients with valuable insights into the disease's impact. Simultaneously, the prophylaxis priority model contributes to optimizing preventive strategies, considering diverse factors such as bleeding risk and treatment efficiency. The incorporation of a user-friendly chat assistance interface serves as a crucial bridge between the complex machine learning models and end-users. This intuitive platform facilitates transparent communication, allowing patients and healthcare providers to interact seamlessly, seek information, and better comprehend the rationale behind severity assessments and prophylaxis recommendations. As we move forward, continuous improvement loops, user feedback integration, and adherence to ethical considerations will be paramount. This innovative approach not only enhances the precision and personalization of haemophilia care but also underscores the potential for technology to positively impact patient outcomes in the realm of rare genetic disorders.

REFERENCES

[1] "**Clinicopathological Parameters of Haemophilia Patients at a Tertiary Care Centre in Northern India",** Anurag Singh, Shalini Rawat, Rashmi Kushwaha, Mili Jain , Shailendra P. Verma , U.S. Singh 1. Pathology, King George's Medical University, Lucknow, IND 2. Clinical Hematology, King George's Medical University, Lucknow, IND.2023

[2] **"Statistical model for detecting probability of Severity Level of Hemophilia**", AKM Raquibul Bashar*and Chris P Tsokos Department of Health Science, University of South Florida, Florida, USA.2021

[3] **"Hemophilias A and B"**. Bolton-Maggs PH, Pasi KJ. Lancet. 2003;361:1801–1809. doi: 10.1016/S0140-6736(03)13405-8.

[4] **"The history of haemophilia in the royal families of Europe"**. Stevens RF,Br J Haematol. 1999;105:25–32.

[5] **"A recent history of haemophilia treatment. Haemophilia. 200"** Mannucci PM. Back8;14(Suppl. 3):10–18.

[6] **"Experience with prophylaxis in Sweden"**. Nilsson IM, Semin Hematol. 1993;30(3 Suppl2):16–19.

[7] **"The management of hemophilia in elderly patients".** Franchini M, Tagliaferri A, Mannucci PM, Clin Interv Aging.

2007;2:361–368. [PMC free article]

[8] **"Prolonged bleeding free period following prophylactic infusion of recombinant factor VIII reconstituted with PEGylated liposomes"**. Spira J, Plyusch OP, Andreeva TA, Andreev Y Blood. 2006;108:3668–3673. doi: 10.1182/blood-2006-03- 008276.